Loading clinical trials...
Loading clinical trials...
Phase II Trial of Y90 Ibritumomab Tiuxetan Post Rituximab-Cyclophosphamide, Doxobrubicn, Vincristine and Prednisone (R-CHOP) Chemotherapy for Newly Diagnosed Patients With Advanced Stage Follicular Lymphoma
Conditions
Interventions
Y90 Ibritumomab Tiuxetan RIT
Locations
1
Canada
Sunnybrook Health Sciences Centre, Odette Cancer Centre
Toronto, Ontario, Canada
Start Date
May 1, 2007
Primary Completion Date
May 1, 2016
Completion Date
May 1, 2016
Last Updated
June 17, 2016
NCT06337318
NCT05006716
NCT06026319
NCT06510361
NCT07128641
NCT01804686
Lead Sponsor
Sunnybrook Health Sciences Centre
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions